Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

920 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: qu r. bioRxiv [Preprint]. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544. bioRxiv. 2023. Update in: Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851 PMID: 37609261 Free PMC article. Updated. Preprint.
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, De Stanchina E, Dela Cruz FS, Kung AL, Gounder M, Kentsis A. Kazansky Y, et al. Among authors: qu r. bioRxiv [Preprint]. 2023 Dec 1:2023.02.06.527192. doi: 10.1101/2023.02.06.527192. bioRxiv. 2023. Update in: Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110 PMID: 36798379 Free PMC article. Updated. Preprint.
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Kazansky Y, Mueller HS, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Mundi PS, Kuwahara Y, Somwar R, Qu R, Califano A, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: qu r. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592420. doi: 10.1101/2024.05.03.592420. bioRxiv. 2024. PMID: 38766189 Free PMC article. Preprint.
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche RP, Qu R, Rosenberg L, Hamard PJ, Bykov Y, Green H, Gusain L, Chiappinelli KB, Ozsoy MA, Chui MH, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Vabret N, Weigelt B, Zamarin D. Brodeur MN, et al. Among authors: qu r. Sci Adv. 2024 Dec 6;10(49):eadk4851. doi: 10.1126/sciadv.adk4851. Epub 2024 Dec 4. Sci Adv. 2024. PMID: 39630912 Free PMC article.
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: qu r. Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110. Cancer Discov. 2024. PMID: 38315003 Free PMC article.
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.
Taniguchi H, Chakraborty S, Takahashi N, Banerjee A, Caeser R, Zhan YA, Tischfield SE, Chow A, Nguyen EM, Villalonga ÁQ, Manoj P, Shah NS, Rosario S, Hayatt O, Qu R, de Stanchina E, Chan J, Mukae H, Thomas A, Rudin CM, Sen T. Taniguchi H, et al. Among authors: qu r. Sci Adv. 2024 Sep 27;10(39):eado4618. doi: 10.1126/sciadv.ado4618. Epub 2024 Sep 27. Sci Adv. 2024. PMID: 39331709 Free PMC article.
920 results